

Supplementary Table S1. Baseline clinicopathological characteristics

Variable	Category	n	%
Histology	Invasive ductal carcinoma	63	90.0
	Mixed type	5	7.1
Clinical Stage at Diagnosis	Stage 2	40	57.2
	Stage 3	30	42.8
Menopausal Status	Premenopausal	31	44.3
	Postmenopausal	39	55.7
Estrogen Receptor (ER)	Positive	41	58.6
	Negative	29	41.4
Progesterone Receptor (PR)	Positive	31	44.3
	Negative	39	55.7
HER2 (CERBB2)	IHC 2+ / FISH-positive	9	12.9
	IHC 3+	61	87.1
Peritumoral Vascular Invasion (PVI)	Present	1	1.4
	Unknown	65	92.9
Lymphovascular Invasion (LVI)	Present	2	2.9
	Unknown	65	92.9
Tumor Grade	Grade 1	10	14.3
	Grade 2	37	52.9
	Grade 3	23	32.9
Neoadjuvant Chemotherapy Regimen	AC + Dual anti-HER2 therapy + Docetaxel (AC+DTP)	68	97.1
	AC + Pertuzumab + Trastuzumab + Weekly Paclitaxel	1	1.4
	TCHP (Docetaxel–Carboplatin–Trastuzumab–Pertuzumab)	1	1.4
Type of Surgery	Mastectomy + ALND	16	22.9
	Mastectomy + SLNB	28	40.0
	Breast-conserving surgery + ALND	7	10.0
	Breast-conserving surgery + SLNB	19	27.1
Pathological Complete Response (pCR)	Yes	42	60.0
	No	28	40.0